10 results about "Macroglobulin" patented technology

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The invention relates to a preparation method and application of alpha2-macroglobulin. The invention finds that the alpha2-macroglobulin can be used for promoting the intercellular effect of cells, and further can be used for preparing medicines for treating osteoarthritis, atherosclerosis, inflammatory aging, tumors, chronic obstructive pulmonary disease, systemic lupus erythematosus and other diseases caused by intercellular function deficiency.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The invention discloses a primer blocker composition for detecting a macroglobulinemia Fahrenheit CXCR4 gene, the primer blocker composition comprises a primer group and a blocker, and the primer group comprises a forward primer group and a reverse primer group; the nucleotide sequence of the blocking agent is as shown in SEQ ID NO. 1; the nucleotide sequence of the reverse primer group is as shown in SEQ ID NO. 2; the nucleotide sequence of the forward primer group is as shown in SEQ ID NO. 3. The invention also discloses a kit containing the composition and a detection method. By accurately detecting the CXCR4 gene, the CXCR4 gene can be combined with other markers, and pathological diagnosis and molecular typing of WM are accurate; a plurality of CXCR4 high-frequency mutation sites of WM can be covered by a single reaction, and compared with a digital PCR method only capable of detecting a single site, the cost is reduced by more than 80%, and the method is suitable for being popularized in hospitals.

The application discloses a sugar chain marker combination for diagnosing Waldenstrom's macroglobulinemia and application thereof, and the marker combination comprises the following N-sugar chains: cFA2_2, cFA2B, cFA2(6)G1, cFA2(3)G1, A2G2, cFA2B(3)G1, cFA2G2, cFA2BG2, A3G3_2 and aFA3G3_2. By analyzing the change of N-sugar chains on glycoprotein in blood, the application finds that specific N-sugar chain marker combination has significant correlation with WM. The marker combination has high sensitivity and high specificity in WM diagnosis, can be rapidly detected through fluorescence labeling technology, has a non-invasive advantage, can be used for early discovery and accurate diagnosis, and is helpful to improve the cure rate and survival rate of patients. In addition, the discovery of the bisecting biantennary N-sugar chain combination provides a new potential treatment target for WM, and has important clinical application value.

Disclosed herein are methods for determining whether a subject is suffering from Waldenström macroglobulinemia (WM) or a precursor condition thereof, or multiple myeloma (MM) or a precursor condition thereof. These methods comprise determining, in a sample obtained from the subject, data indicative of the proportions of two or more immune cell populations. Methods of monitoring a subject with WM, or a precursor condition thereof, are also disclosed. These methods comprise determining in tumor cells obtained from a sample obtained from the subject and a reference sample expression of two or more gene expression signatures which indicate whether the subject is at risk of disease progression.

The present invention relates to a method for diagnosing the risk of non-alcoholic steatohepatitis (NAS) in a human patient with a metabolic disorder, comprising: (i) calculating a non-alcoholic fatty liver disease (NFD) score from the patient's age, body mass index (BMI), aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ratio, platelet count, and hyperglycemic status; and (ii) calculating a non-alcoholic steatohepatitis score (NIS4) for the patient based on the levels of hsa-miR-34a-5p, alpha-2-macroglobulin (A2M), YKL-40, and glycosylated hemoglobin (HbA1c), measured in a blood sample or blood derivative from the patient; and determining the presence or absence of NAS risk in the patient based on these scores. where the NFS test is implemented before or after the NIS4 test.

Disclosed herein are methods for determining whether a subject is suffering from Waldenström macroglobulinemia (WM) or a precursor condition thereof, or multiple myeloma (MM) or a precursor condition thereof. These methods comprise determining, in a sample obtained from the subject, data indicative of the proportions of two or more immune cell populations. Methods of monitoring a subject with WM, or a precursor condition thereof, are also disclosed. These methods comprise determining in tumor cells obtained from a sample obtained from the subject and a reference sample expression of two or more gene expression signatures which indicate whether the subject is at risk of disease progression.

A pharmaceutical composition comprising α2-macroglobulin (A2M) and a serine protease protein such as porcine pancreatic elastase (PPE) is provided, wherein A2M and the serine protease protein such as PPE are bound as a protein complex, and this protein complex retains the CD95 protease cleavage activity and cancer cell killing activity of the serine protease, while sterically inhibiting the binding of the serine protease to fibrinogen and a serine protease inhibitor. Related methods of use and manufacturing for treating diseases such as cancer are also provided.